Basilea News http://www.basilea.com/ Basilea News en Tue, 30 Aug 2016 09:17:36 +0200 Tue, 30 Aug 2016 09:17:36 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region]]> http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Hikma-for-CRESEMBA-isavuconazole-in-the-MENA-region/75a0847f-c0d8-b2e5-133a-34b99f982bf6
  • Basilea extending its agreement with Hikma to include antifungal CRESEMBA® in addition to antibiotic Zevtera®
  • ]]>
    Wed, 17 Aug 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Hikma-for-CRESEMBA-isavuconazole-in-the-MENA-region/75a0847f-c0d8-b2e5-133a-34b99f982bf6
    <![CDATA[Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets]]> http://www.basilea.com/News-and-Media/Basilea-reports-2016-half-year-results-CRESEMBA-launched-in-key-European-markets/af0d2479-4963-6f53-99b2-85dae0ce489b
  • Antifungal CRESEMBA® (isavuconazole) launched in first European markets
  • Entered contract with BARDA for the development and potential US registration of the antibiotic ceftobiprole (European trade name Zevtera® or Mabelio®)
  • Half-year cash and financial investments of CHF 311 million
  • ]]>
    Mon, 15 Aug 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-2016-half-year-results-CRESEMBA-launched-in-key-European-markets/af0d2479-4963-6f53-99b2-85dae0ce489b
    <![CDATA[Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy]]> http://www.basilea.com/News-and-Media/Basileas-antifungal-CRESEMBA-isavuconazole-launched-in-Italy/20f7ff0b-bd95-beb9-6ae6-122f352d592a Mon, 27 Jun 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basileas-antifungal-CRESEMBA-isavuconazole-launched-in-Italy/20f7ff0b-bd95-beb9-6ae6-122f352d592a <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting]]> http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-ASCO-meeting/0ac65095-e31b-3ee8-d3fc-2821b95d15f8
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
  • ]]>
    Thu, 09 Jun 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-ASCO-meeting/0ac65095-e31b-3ee8-d3fc-2821b95d15f8
    <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7032e387-fcb9-325b-58b2-57a72787c2e8 Thu, 21 Apr 2016 18:30:10 +0200 http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7032e387-fcb9-325b-58b2-57a72787c2e8 <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting]]> http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-AACR-meeting/101f964b-f449-654c-6ec0-c0ec3963b0e4
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
  • ]]>
    Thu, 21 Apr 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-AACR-meeting/101f964b-f449-654c-6ec0-c0ec3963b0e4
    <![CDATA[Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program]]> http://www.basilea.com/News-and-Media/Basilea-awarded-contract-by-BARDA-of-up-to-USD-100-million-funding-for-ceftobiprole-phase-3-program/5d28fd52-0d0d-34f5-7f08-69db2d2d600e Wed, 20 Apr 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-awarded-contract-by-BARDA-of-up-to-USD-100-million-funding-for-ceftobiprole-phase-3-program/5d28fd52-0d0d-34f5-7f08-69db2d2d600e <![CDATA[Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)]]> http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-isavuconazole-and-ceftobiprole-data-at-European-Congress-of-Clinical-Microbiology-and-Infectious-Diseases-ECCMID/fe0cb1e4-64f9-af59-f229-f45d9b80f15c
  • Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia
  • ]]>
    Fri, 15 Apr 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-isavuconazole-and-ceftobiprole-data-at-European-Congress-of-Clinical-Microbiology-and-Infectious-Diseases-ECCMID/fe0cb1e4-64f9-af59-f229-f45d9b80f15c
    <![CDATA[Basilea issues agenda for Annual General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-issues-agenda-for-Annual-General-Meeting-of-Shareholders/8084cc62-a399-5d4a-9e10-daa99c187b4f
  • Dr. Martin Nicklasson has determined not to stand for re-election as Chairman but will stand for re-election as Member of the Board
  • Domenico Scala nominated as new Chairman of the Board
  • ]]>
    Tue, 15 Mar 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-issues-agenda-for-Annual-General-Meeting-of-Shareholders/8084cc62-a399-5d4a-9e10-daa99c187b4f
    <![CDATA[Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis]]> http://www.basilea.com/News-and-Media/Basilea-announces-that-The-Lancet-Infectious-Diseases-published-results-from-the-CRESEMBA-isavuconazole-open-label-study-for-the-treatment-of-mucormycosis/8654679f-7fd0-7ff7-e0c3-f3985a13ec37 Wed, 09 Mar 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-announces-that-The-Lancet-Infectious-Diseases-published-results-from-the-CRESEMBA-isavuconazole-open-label-study-for-the-treatment-of-mucormycosis/8654679f-7fd0-7ff7-e0c3-f3985a13ec37